Expertise

Franjo Hanzl

Vice President Commercial Development Europe

Expertise:

Brand Plan Development, Commercialization, Demand Planning, Employee Development, Field Sales & Reimbursement, Forecasting Activities, Immuno-oncology, KPI Planning, Launch Readiness, Leadership, Management, Marketing and Advertising, Product Launch, Sales

As a leader of the commercial team in Europe, Franjo helps clients solve complex industry challenges while supporting streamlined commercialisation strategies that get innovative therapies to patients across borders. He joined EVERSANA with more than 25 years of experience in the life sciences industry and has led global launches across six continents in his career. Franjo has extensive expertise in marketing, business development, and pharmaceutical partnership and alliance management through his work with branded and generic pharma in Europe, which also provides him with a deep knowledge of the pricing landscape.

Franjo holds a master’s degree in pharmacy from the University of Zagreb in Croatia.

Articles by Franjo Hanzl

Why Launching in Europe Is Unlike Launching Anywhere Else

Today, there are more than half a billion people in the European Union (EU) and United Kingdom (U.K.). Passing over this part of the globe puts patients and manufacturers at risk for negative outcomes. Launching a new therapy in the EU and U.K. has traditionally involved complex navigation of service providers, price sequencing and the […]

Simplifying EU Distribution to Maximize Cost Efficiency and Speed to Market for Patients and Manufacturers

COVID-19 ignited a spark of innovation in the healthcare industry, forcing global markets to reconsider drug development and commercialization processes. The European Union (EU), specifically, is taking carefully planned steps into a new phase of pharma with recent changes, including the Pharmaceutical Strategy for Europe. But one element of the European pharma industry that remains […]

Interested in scheduling a meeting or speaking event?

문의

  • This field is for validation purposes and should be left unchanged.